NVO Financials: Novo Nordisk A/S AI Analysis

Q: What are Novo Nordisk A/S's key financial statements?

According to the latest financial statement (Form-10K), Novo Nordisk A/S has a total asset of $465,795, Net profit of $100,988

Q: What are the key financial ratios for NVO?

Novo Nordisk A/S's Current ratio is 1.44, has a Net margin is 34.77, sales per share of $65.06.

Q: How is Novo Nordisk A/S's revenue broken down by segment or geography?

Novo Nordisk A/S largest revenue segment is Victoza, at a revenue of 5,482,000,000 in the most earnings release.For geography, US Revenue is the primary market for Novo Nordisk A/S, at a revenue of 167,404,000,000.

Q: Is Novo Nordisk A/S profitable?

yes, according to the latest financial statements, Novo Nordisk A/S has a net profit of $100,988

Q: Does Novo Nordisk A/S have any liabilities?

yes, Novo Nordisk A/S has liability of 322,309

Q: How many outstanding shares for Novo Nordisk A/S?

Novo Nordisk A/S has a total outstanding shares of 4,441

Home

Stock

NVO

NVO Financial

Novo Nordisk A/S

$60.33

-4.07%

$-2.56

At close: Jan 28, 16:00:00 GMT-5

$59.83

-0.82%

$-0.5

Pre-market: Jan 29, 07:54:54 GMT-5

Overview Forecast Earnings Dividends Financials

Income

Balance sheet

Cash flow

Annual

Quarterly

NVO Income

Financials in millions USD. Fiscal year is February - January.

Breakdown	TTM	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020
Revenue	315,603	290,403	232,261	176,954	140,800	126,946
Revenue Growth (YoY)	17%	25%	31%	26%	11%	4%
Cost of Revenue	56,664	43,560	35,765	28,448	23,658	20,932
Gross Profit	258,939	246,843	196,496	148,506	117,142	106,014
Selling, General & Admin	73,122	66,546	60,767	49,932	40,409	36,108
Research & Development	51,193	38,021	29,373	21,761	16,292	13,713
Operating Expenses	126,280	107,942	91,798	72,837	57,784	51,411
Other Non Operating Income (Expenses)	--	-289	-197	-181	-122	-150
Pretax Income	131,912	127,191	104,674	69,062	59,080	53,130
Income Tax Expense	28,139	26,203	20,991	13,537	11,323	10,992
Net Income	103,773	100,988	83,683	55,525	47,757	42,138
Net Income Growth	10%	21%	51%	16%	13%	8%
Shares Outstanding (Diluted)	4,446.8	4,463	4,494.8	4,544.6	4,606.2	4,680
Shares Change (YoY)	0%	-1%	-1%	-1%	-2%	-2%
EPS (Diluted)	23.33	22.63	18.62	12.22	10.37	9
EPS Growth	10%	22%	52%	18%	15%	10%
Free Cash Flow	60,950	69,659	70,012	64,134	47,615	29,870
Free Cash Flow Per Share	--	--	--	--	--	--
Gross Margin	82.04%	85%	84.6%	83.92%	83.19%	83.51%
Operating Margin	42.03%	47.83%	45.07%	42.76%	42.15%	43.01%
Profit Margin	32.88%	34.77%	36.02%	31.37%	33.91%	33.19%
Free Cash Flow Margin	19.31%	23.98%	30.14%	36.24%	33.81%	23.52%
EBITDA	154,277	158,008	114,111	83,031	65,383	60,356
EBITDA Margin	48.88%	54.4%	49.13%	46.92%	46.43%	47.54%
D&A For EBITDA	21,618	19,107	9,413	7,362	6,025	5,753
EBIT	132,659	138,901	104,698	75,669	59,358	54,603
EBIT Margin	42.03%	47.83%	45.07%	42.76%	42.15%	43.01%
Effective Tax Rate	21.33%	20.6%	20.05%	19.6%	19.16%	20.68%

Follow-Up Questions

What are Novo Nordisk A/S's key financial statements?



What are the key financial ratios for NVO?



How is Novo Nordisk A/S's revenue broken down by segment or geography?



Is Novo Nordisk A/S profitable?



Does Novo Nordisk A/S have any liabilities?



How many outstanding shares for Novo Nordisk A/S?



Key Stats

Prev.Close

$62.89

Open

$61.48

Day's Range

$59.83 - $61.55

52 week range

$43.08 - $93.8

Volume

16.0M

Avg.Volume

20.6M

EPS (TTM)

3.67

Dividend yield

Market Cap

$201.5B

What is Novo Nordisk A/S?

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. The firm is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The firm operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The firm's diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs. The firm's biopharmaceuticals segment covers the therapy areas of hemophilia care, growth hormone therapy and hormone replacement therapy. The firm also offers Saxenda product to treat obesity. The company offers a range of products, including NovoLog/NovoRapid; NovoLog Mix/NovoMix; Prandin/NovoNorm; NovoSeven; Norditropin, and Vagifem. As of December 31, 2016, it marketed its products in over 180 countries. Its regional structure consists of two commercial units: North America and International Operations.



Features

AI Copilot for Stock & Crypto

Trading Strategies

Megabrain Investors Picks

Trading Mindshare